Thrombotic Risk Assessment
Use
The Thrombotic Risk Assessment is a coagulation profile designed to detect both acquired and congenital causes of thrombophilia, providing a broad evaluation of thrombotic risk. The acquired component includes anticardiolipin antibodies (IgA, IgG, IgM), antiphosphatidylserine antibodies (IgG, IgM), β2-glycoprotein 1 antibodies (IgA, IgG, IgM), lupus anticoagulant reflex, and thrombin mixing study. The congenital component assesses activated protein C resistance (APCR), antithrombin activity, protein C functional activity, and free protein S level. Results support risk assessment and clinical decision-making for patients with personal or family history of venous thromboembolism or thrombophilia risk factors.
Special Instructions
If the patient’s hematocrit exceeds 55%, the volume of citrate in the collection tube must be adjusted. Refer to Coagulation Collection Procedures for guidance.
Limitations
Not provided.
Methodology
Other
Biomarkers
Result Turnaround Time
3-7 days
Related Documents
For more information, please review the documents below
Specimen
Plasma
Volume
2.6 mL
Minimum Volume
Not provided
Container
Blue-top (sodium citrate) tube
Collection Instructions
Collected in blue-top 3.2% buffered sodium citrate tube; filled to completion; gently inverted, double centrifugation, plasma transferred via plastic pipette into Labcorp PP transpak frozen purple tube (Labcorp No. 49482), freeze immediately and maintain frozen.
Storage Instructions
Freeze plasma
Other tests from different labs that may be relevant
